CONJUGATED ESTROGENS
Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Conjugated estrogens bind to estrogen receptors (ERα and ERβ), modulating gene transcription and exerting estrogenic effects on target tissues, including the endometrium, breast, and bone. They increase hepatic synthesis of sex hormone-binding globulin (SHBG), thyroid-binding globulin, and other proteins, and have effects on lipid metabolism, coagulation factors, and vasodilation via nitric oxide.
| Metabolism | Primarily hepatic metabolism via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2C9, CYP2C19) and conjugation (glucuronidation, sulfation). Enterohepatic recirculation occurs. Metabolites are excreted in urine and bile. |
| Excretion | Renal: 40–50% as glucuronide conjugates; biliary/fecal: ~20% as free and conjugated forms. |
| Half-life | 10–24 hours (terminal); clinical context: requires daily dosing for stable hormone levels. |
| Protein binding | 98–99% bound to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | 1.4–2.2 L/kg; indicates extensive distribution into tissues, including breast and reproductive organs. |
| Bioavailability | Oral: 30–50% due to extensive first-pass metabolism; transdermal: ~100%. |
| Onset of Action | Oral: 2–4 weeks for vasomotor symptom relief; transdermal: 2–4 weeks. |
| Duration of Action | 24 hours; clinical notes: daily administration required for continuous effect. |
| Molecular Weight | 338.48 |
0.625 mg orally once daily for menopausal symptoms; 1.25 mg orally three times daily for 2-3 weeks for abnormal uterine bleeding; 25 mg intravenously or intramuscularly every 6-12 hours for postpartum hemorrhage.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment is recommended based on GFR; use with caution in severe renal impairment due to potential fluid retention. |
| Liver impairment | Contraindicated in Child-Pugh class C (severe hepatic impairment). Dose adjustment not defined for Child-Pugh A or B; avoid use if active liver disease. |
| Pediatric use | Not approved for use in children; no established weight-based dosing. Use only in specific conditions like Turner syndrome under specialist guidance. |
| Geriatric use | Use lowest effective dose for shortest duration due to increased risks of DVT, stroke, and dementia. No specific dose adjustment, but monitor for adverse effects. |
| 1st trimester | Contraindicated. Use during pregnancy is associated with increased risk of congenital anomalies, including cardiac defects and limb reduction defects. Estrogens should not be used in pregnancy. |
| 2nd trimester | Contraindicated. Fetal exposure may cause delayed adverse effects on reproductive development. Not indicated for use during pregnancy. |
| 3rd trimester | Contraindicated. Use may lead to urogenital abnormalities in offspring and increase risk of endometrial cancer in later life. Avoid during labor and delivery. |
Clinical note
Inducers of CYP450 enzymes (eg carbamazepine) may decrease estrogen levels Increases risk of thromboembolic disorders and endometrial cancer.
| Placental transfer | Estrogens cross the placenta readily. Fetal exposure is significant, with potential for adverse developmental effects. |
| Breastfeeding | Estrogens are excreted in human milk. Use during breastfeeding may reduce milk production and quality. Not recommended for nursing mothers. If used, monitor infant for estrogenic effects. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in postmenopausal women. Do not use estrogen-alone therapy in women with a uterus without concomitant progestin. Estrogen plus progestin therapy increases the risk of stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction in postmenopausal women. Estrogen plus progestin therapy increases the risk of invasive breast cancer. Estrogen-alone therapy increases the risk of stroke and deep vein thrombosis. Do not use estrogens for the prevention of cardiovascular disease or dementia.
| Common Effects | osteoporosis prevention |
| Serious Effects |
Breast cancer (known, suspected, or history of)Estrogen-dependent neoplasia (e.g., endometrial cancer)Undiagnosed abnormal genital bleedingActive or past history of venous thromboembolism (e.g., deep vein thrombosis, pulmonary embolism)Active or past arterial thromboembolic disease (e.g., stroke, myocardial infarction)Known or suspected pregnancySevere hepatic impairment or diseaseKnown hypersensitivity to conjugated estrogens or any component
| Precautions |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | Conjugated estrogens are contraindicated in pregnancy. First trimester: increased risk of fetal genital tract abnormalities (e.g., vaginal adenosis, cervical ectropion) and potential transplacental carcinogenesis (clear cell adenocarcinoma in female offspring). Second and third trimesters: no established safe use; may cause fetal harm. U.S. FDA Pregnancy Category X. |
| Fetal Monitoring | Not applicable in pregnancy (contraindicated). For inadvertent exposure: monitor fetal growth, amniotic fluid index, and consider fetal echocardiography for potential cardiovascular effects. No routine monitoring recommended for lactation. |
| Fertility Effects | Conjugated estrogens may impair fertility by suppressing gonadotropin secretion, inhibiting ovulation, and altering endometrial receptivity. Use for contraception or hormone therapy can temporarily reduce fecundity. Effects are reversible upon discontinuation. |
| Cardiovascular disorders: increased risk of stroke, DVT, PE, MI, Malignant neoplasms: endometrial cancer, breast cancer (especially with progestin), Dementia: possible increased risk in women ≥65 years, Gallbladder disease, Hypertriglyceridemia, Fluid retention, Hypocalcemia in hypoparathyroidism, Retinal vascular thrombosis, Hereditary angioedema exacerbation, Impaired liver function or history of cholestatic jaundice, Exacerbation of endometriosis, Uterine leiomyomata, Porphyria exacerbation |
| Food/Dietary | Grapefruit juice may inhibit CYP3A4 metabolism of estrogens, increasing serum levels; avoid concurrent use. No specific dietary restrictions, but maintain a balanced diet to manage weight and blood pressure. Limit alcohol intake as it may increase estrogen levels and risk of breast cancer. |
| Clinical Pearls | Conjugated estrogens are derived from pregnant mare urine and contain a mixture of estrogens, primarily estrone sulfate. Use the lowest effective dose for the shortest duration. Risk of endometrial cancer increases with unopposed estrogen use in women with intact uteri; prescribe with a progestin. Contraindicated in breast cancer, active thromboembolic disorders, liver impairment, and unexplained vaginal bleeding. Monitor for signs of thromboembolism, hypertension, and gallbladder disease. |
| Patient Advice | Take this medication exactly as prescribed; do not increase dose or frequency. · Report any signs of blood clots (sudden chest pain, shortness of breath, leg swelling), stroke (sudden numbness, confusion, vision changes), or gallbladder problems (right upper abdominal pain). · If you have a uterus, you must take a progestin as directed to reduce the risk of endometrial cancer. · Do not use during pregnancy or while breastfeeding. · Common side effects include nausea, breast tenderness, and vaginal bleeding or spotting; notify your provider if bleeding is heavy or persistent. · Attend regular physical exams, including breast exams and mammograms, as recommended. |